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Abstract
Background: International travel contributes to the spread of antibiotic resistant bacteria over the world. Most
studies addressing travel-related changes in the faecal flora have focused on specific mobile resistance genes, or
depended on culturing of individual bacterial isolates. Antibiotic resistance can, however, also spread via travellers
colonized by bacteria carrying chromosomal antibiotic resistance mutations, but this has received little attention so
far. Here we aimed at exploring the abundance of chromosomal quinolone resistance mutations in Escherichia
communities residing in the gut of Swedish travellers, and to determine potential changes after visiting India.
Sweden is a country with a comparably low degree of quinolone use and quinolone resistance, whereas the
opposite is true for India.
Methods: Massively parallel amplicon sequencing targeting the quinolone-resistance determining region of gyrA
and parC was applied to total DNA extracted from faecal samples. Paired samples were collected from 12 Swedish
medical students before and after a 4–15 week visit to India. Twelve Indian residents were included for additional
comparisons. Methods known resistance mutations were common in Swedes before travel as well as in Indians,
with a trend for all mutations to be more common in the Indian sub group. There was a significant increase in the
abundance of the most common amino acid substitution in GyrA (S83L, from 44 to 72 %, p = 0.036) in the samples
collected after return to Sweden. No other substitution, including others commonly associated with quinolone
resistance (D87N in GyrA, S80I in ParC) changed significantly. The number of distinct genotypes encoded in each
traveller was significantly reduced after their visit to India for both GyrA (p = 0.0020) and ParC (p = 0.0051),
indicating a reduced genetic diversity, similar to that found in the Indians.
Conclusions: International travel can alter the composition of the Escherichia communities in the faecal flora,
favouring bacteria carrying certain resistance mutations, and, thereby, contributes to the global spread of antibiotic
resistance. A high abundance of specific mutations in Swedish travellers before visiting India is consistent with the
hypothesis that these mutation have no fitness cost even in the absence of an antibiotic selection pressure.
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Background
Bacterial antibiotic resistance is one of the greatest threats
to public health globally. Bacteria can acquire resistance
by gaining mobile antibiotic resistance genes or by de novo
mutations in pre-existing DNA. International travel has
been identified as one of the facilitators of the global
spread of resistant bacteria, together with, e.g., trade and
migration [1, 2]. Indeed, in both population-based case-
control studies [3] and time series studies [4, 5] using clas-
sical culturing of bacteria, it has been shown that inter-
national travel is associated with an increased abundance
of resistant bacteria in the gut flora. Studies utilising PCR
to assess the presence of resistance genes in gut micro-
biota have demonstrated the acquisition of such genes
after international travel [6–8]. However, little is known
about how travel affects the relative abundance of resist-
ance mutations in human microbiota.
Fluoroquinolone antibiotics are a clinically important
class of broad-spectrum antibiotics to which bacteria
have acquired a high frequency of resistance in many
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parts of the world [9]. Fluoroquinolones inhibit type II
topoisomerases, DNA gyrase and topoisomerase VI,
which are enzymes that introduce double-stranded
breaks in DNA to maintain DNA topology during repli-
cation and transcription. Both enzymes are tetramers
(X2Y2), where DNA gyrase encoded by genes gyrA and
gyrB, and topoisomerase IV is encoded by parC and
parE. Resistance against fluoroquinolones is caused by ei-
ther chromosomal mutations in the quinolone-resistance
determining region (QRDR) of the target genes, especially
in gyrA and parC [10], or by mobile resistance genes (qnr,
qepA, oqxAB, or aac(6′)-Ib-cr) [11]. Plasmid-mediated
quinolone resistance, however, usually confers a lower level
of resistance than chromosomal mutations. A study of
fluoroquinolone-resistant clinical E. coli isolates in Hous-
ton, TX, USA, showed that all isolates had one or several
amino acid substitutions in GyrA, and 85 % of these iso-
lates had additional substitutions in ParC [12]. The gene
aac(6′)-lb-cr was only detected in isolates that also pos-
sessed chromosomal mutations, and none of the studied
isolates carried qnrA. These results underline that chromo-
somal mutations in gyrA and parC are the main causes of
clinical resistance to fluoroquinolones.
In Sweden fluoroquinolones constituted 5.9 % of the
total consumption of antibacterials for systemic use in
2010 (0.77 and 0.164 Defined Daily Doses, DDD, per 1
000 inhabitants and day in the primary care sector and
the hospital sector, respectively) [13], and in 2011, 7.9 %
of all tested invasive E. coli infections were fluoroquino-
lone resistant [14]. During the same years, the average
consumption of fluoroquinolones in the primary care
sector in Europe was 1.44 DDD per 1 000 inhabitants
and year (excluding countries only reporting total sales),
and the average frequency of resistance in invasive E.
coli was 23 %. Sweden is, therefore, a country with both
a low fluoroquinolone consumption and a low fluoro-
quinolone resistance burden. Although India lacks a na-
tional surveillance system for both antibiotic consumption
and resistance, there are reports from some areas. When
antibiotic usage in private clinics in New Delhi, India, was
studied in 2008, approximately 33 % of the consumed
DDD of antibiotics were fluoroquinolones (estimated 74
DDD per 1 000 patients and day) [15]. Furthermore, a
study of resistance in uropathogens isolated in a tertiary-
care hospital in the south of India found that 73.1 % of the
E. coli isolates were ciprofloxacin resistant [16]. Hence,
both fluoroquinolone consumption and resistance levels
in, at least, bacteria causing urinary tract infections are
higher in parts of India compared to Sweden. The differ-
ence in antibiotic resistance burden is also supported by
findings of the spread of mobile resistance genes from
India to Sweden. For example, the metallo-β-lactamase
NDM-1 was isolated from a Swedish patient returning
from India [17]. Moreover, a prospective study of Swedish
travellers found that, out of the studied countries,
India was the country associated with the highest risk
of acquiring CTX-M-type extended spectrum β-
lactamases (ESBLs) to the gut (88 % of travellers visit-
ing India) [18]. A study of Swedish patients suffering
from traveller’s diarrhoea showed that 79 % of travellers to
India, but only 3 % of patients travelling within Europe, had
ESBL-producing bacteria in their stool [8]. Lastly, travel
from Sweden to the Indian subcontinent has been associ-
ated with a significantly increased risk of acquiring ESBL-
producing Enterobacteriaceae into the faecal flora [5].
In this study, we assessed the effect of travelling from
Sweden to India on the abundance of quinolone resist-
ance mutations in faecal Escherichia communities. Mas-
sively parallel amplicon sequencing of metagenomic
DNA isolated from paired samples collected from
Swedes before and after their visit to India, was used to
determine the sequence of the QRDR of gyrA and parC.
By using this method, we could study resistance muta-
tions in an bacterial community without relying on cul-
turing of individual bacteria. Samples from an Indian
sub-population were also included and provided add-
itional references.
Methods
Paired faecal samples were collected from 12 Swedish
students from Universities in Umeå, Stockholm, and
Gothenburg between December 2010 and February
2013, before and after their visit to India for internship
or study at hospitals. The volunteers were 20–30 years
old, 75 % were female, and the duration of the visit was
28–106 days, during which 67 % of the participants had
regular contact with patients. Samples were collected 1–
77 days before departure (on average, 13 days) and 2–44
days after returning to Sweden (on average, 22 days) (see
Additional file 1: Table S1 and S2). The samples were
collected by the volunteers themselves at home, sent to
the lab in sterile tubes, and stored at −20 °C upon arrival
the following day. We also had access to faecal samples
collected from native Indians living in a rural area near
Hyderabad. Despite them not being matched to the
Swedish participants, 12 of these samples were included
in this study for additional comparisons. The Indian
sampling was carried out in July 2010, the age span of
the participants was 12–40 years, and 33 % were female
(see Additional file 1: Table S1). We have previously
studied environmental fluoroquinolone pollution near
Hyderabad and, therefore, can state that the Indian par-
ticipants all lived in villages where no fluoroquinolones
have been detected in either well water or soil [19].
None of the volunteers in the study, neither Swedes nor
Indians, had taken any antibiotics within six months
prior to the sampling. The Swedish sampling was ap-
proved by the regional ethical review board in Umeå,
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Sweden (2011-357-32M), and institutional ethical clear-
ance (IEC, National Centre for Cell Science, Pune, India)
was obtained for the Indian sampling. Written informed
consent was obtained from all participants. DNA extrac-
tion was performed using the QIAamp® DNA Stool Mini
Kit (QIAGEN) according to the manufacturer’s protocol.
The DNA concentrations were measured using a Nano-
Drop, and the samples were stored at −20 °C before
PCR amplification of the target genes.
Using Primer3Plus, primers were designed targeting
the QRDR of gyrA and parC. The QRDR was defined as
the region of each gene including all resistance muta-
tions in E. coli reported by Ruiz [20] and was given as
the target region in Primer3Plus. To capture as large a
proportion of the Escherichia community as possible, all
Escherichia sequences annotated as gyrA or parC were
downloaded from Pathosystems Resource Integration
Center (PATRIC) [21], and MUSCLE [22] was used to
produce one multiple sequence alignment for each gene.
Because the Shigella genus is indistinguishable from
Escherichia in nucleotide sequence in the target region
of both gyrA and parC, all Shigella gyrA and parC se-
quences in PATRIC were also added to the multiple se-
quence alignment. Variable positions in the alignments
were given as excluded regions in Primer3Plus, and the
product size range was set to 250–350 bp, close to the
average length of a 454 sequence read. The top ten pri-
mer pairs for each gene suggested by the software were
tested experimentally, and the primer pair producing
most amplicons with the expected target length, as de-
termined using gel electrophoresis, was selected for the
study. The selected primer sequences, target region, ex-
pected target size, and annealing temperature are listed
in Table 1.
The PCR amplification of QRDRs was performed as
follows: 1xGotaq®Reaction buffer, 0.2 mM dNTP Mix,
0.4 μM forward primer, 0.4 reverse primer, 1.25u GoTaq®
DNA polymerase (Promega Corporation), 50 ng tem-
plate, and water up to 25 μl were mixed in sterile 0.2 μg
tubes. The PCR amplification included an initial de-
naturation at 95 °C for 2 min, denaturation at 95 °C for
10 s, annealing at 57–61 °C for 30 s, extension at 72 °C
for 1 min, and a final extension for 7 min. To ensure a
sufficient yield of amplicon DNA, PCR was run for 40 cy-
cles. The PCR products were separated using 1.5 % agar-
ose gel electrophoresis and visualised with GelRed. The
DNA fragments matching the target length were excised
from the gel, placed in a microcentrifuge tube, and
extracted using the GeneJET™ gel extraction kit (Fermentas
International Inc.) according to the manufacturer’s proto-
col. Purified gyrA and parC amplicons originating from the
same faecal sample were pooled and stored at −20 °C be-
fore sequencing.
GATC Biotech (Konstanz, Germany) performed the
massively parallel pyrosequencing with the GS FLX Sys-
tem using Titanium chemistry. Tagged adaptor se-
quences were added to the amplicons using titanium
chemistry and fusion primers before all samples were
pooled and sequenced on one full plate. GS Amplicon
Variant Analyzer from 454 (version 2.5p1) was used to
align the de-multiplexed data onto reference gene se-
quence of gyrA and parC belonging to E. coli K-12
MG1655 [RefSeq: NC_000913.3]. The multiple align-
ments were exported in FASTA format, producing one
alignment file for each gene and sample. To remove
frameshifts caused by homopolymer sequencing errors,
any positions in the multiple alignments having a gap in
the reference sequence were removed. Any remaining
gaps in the read sequences were substituted with the ref-
erence sequence in the corresponding alignment pos-
ition. The resulting gapless reads were translated using
the EMBOSS tool Transeq [23] with the bacterial codon
table (gyrA: reading frame 1, parC: reading frame 2). To
remove reads from untargeted genera, all sequences an-
notated with gene symbol gyrA or parC were down-
loaded from the Comprehensive Microbial Resource
(CMR) [24] and matched to all reads using BLASTn
[25]. Only reads with their best hit to Escherichia or
Shigella and with E-values less than 1 × 10−100 were used
in this study; this reduced the risk of interpreting inter-
species variability as substitutions in the targeted genera.
The number of observed genotypes in a sample was
measured as the number of unique amino acid se-
quences detected in more than 0.5 % of the total number
of analysed reads in the sample. Differences between the
Swedish samples taken before travel to India and the
samples taken after return were tested using a paired t-
test with a two-tailed distribution. The Swedish samples
taken before travel and the Indian samples were com-
pared using a two-sample t-test with a two-tailed distri-
bution assuming equal variance.
Results
The sequencing produced 291 × 106 bp distributed over
almost one million reads (on average, 24 692 reads per
sample). The alignment of the reads matched 38 and 58
Table 1 Selected primers with target regions and experimental setup
Gene Target region Product size Forward primer Reverse primer Annealing T
gyrA 129–439 311 bp ggtacaccgtcgcgtacttt caacgaaatcgaccgtctct 57 °C
parC 20–306 287 bp gccttgcgctacatgaattt accatcaaccagcggataac 57 °C
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% of all reads onto the gyrA and parC reference se-
quences from E. coli K-12 MG1566, respectively (4 %
did not align to either). After discarding reads that were
too dissimilar from Escherichia and Shigella reference
sequences, 53 % of the reads aligned to gyrA remained
for further analysis, and 96 % of the reads aligned to
parC (Additional file 1: Table S1). Due to high frequency
of reads matching Citrobacter, the loss of data in the fil-
tering step was higher for the gyrA data compared to the
parC data. This implies that the parC primers are more
specific for the genus Escherichia.
The abundance of amino acid substitutions was re-
corded in each sample by comparing translated read se-
quences to the reference peptide sequence. The average
substitution abundance in each sampled group, and for
each gene, is illustrated in Fig. 1. In GyrA, amino acids S
83 and D 87 where the most commonly substituted
amino acids, and S83L and D87N where the most de-
tected substitutions. Of all the reads encoding the D87N
substitution, 98 % also encoded the S83L substitution.
There was a significant increase (0.28 increase in rela-
tive abundance, p = 0.036) in the abundance of the most
commonly detected substitution, S83L, when comparing
the Swedish samples collected before travel to India to the
samples taken after return to Sweden (Fig. 2). In the ParC
protein, amino acid S 80 was the most commonly
substituted, with substitution S80I being the most de-
tected substitution. No other substitutions occurred in
more than 5 % of all the analysed reads, but all the substi-
tutions detected in more than 1 % of all reads are listed in
the Additional file 1: Table S3. There were no significant
differences between the Indian samples and the Swedish
samples taken before travel in terms of the abundance of
the common substitutions (p > 0.05).
The Swedish samples collected before travel to India
showed a higher number of observed genotypes com-
pared to both the samples collected after return (GyrA
p = 0.00197, ParC p = 0.00506), and the Indian samples
(GyrA p = 0.0016, ParC p = 0.0045) (Fig. 3). There was,
however, no difference between the Swedish post-travel
samples and the Indian samples with regard to the num-
ber of genotypes.
To investigate the possible co-occurrence of gyrA and
parC mutations at the community level, their relative
abundances were illustrated in a scatter plot (Fig. 4).
The correlation between the abundance of the double
substitution of S83L and D87N in GyrA and the S80I
substitution in ParC was high (sample correlation coeffi-
cient 0.686). To determine whether this correlation
holds for other Escherichia communities, environmental
data were added to the scatter plot. The data were gen-
erated using the same primers and analyses described in
the current study but using sediment samples (Johnning
et al. unpublished), and the same pattern was observed.
Discussion
For some types of antibiotics, including fluoroquino-
lones, chromosomal mutations play a more important
role than horizontally transferrable resistance genes in
the development of clinically resistant pathogens [12].
Here, we have determined how the abundance of
chromosomal fluoroquinolone resistance mutations in
the human gut microbiota changes after travelling from
Sweden, a country with low fluoroquinolone consump-
tion and resistance, to India, a country with relatively
high consumption and resistance. The significant in-
crease in the S83L substitution in GyrA – one of the tar-
get proteins for quinolones – shows that the Escherichia
communities residing in the gut of the Swedes were al-
tered during their stay in India in a direction towards a
higher resistance potential. Furthermore, travel was asso-
ciated with a significant reduction in the number of ob-
served genotypes. Hence, this study illustrates that travel
not only contributes to the spread of mobile antibiotic re-
sistance genes but could also promote the spread of bac-
teria carrying chromosomal resistance mutations.
It is plausible that the increase in resistance mutations
is the result of local strains, obtained from e.g. Indian
water and food [26], colonizing the gut of the Swedish
study participants. Opportunities for changes in the gut
microbiome while travelling are indeed ample. All but
one of the Swedish participants (individual 193) suffered
from traveller’s diarrhoea – a very common fate for
Swedes visiting India [27] – and such a disturbance of
the flora could provide niches that are easily filled by in-
digenous bacterial strains. Alternatively, the bacteria
causing the diarrhoea could be carrying the resistance
mutations. Indeed, the only Swede in this study that
eluded diarrhoea showed a moderate decrease in the
abundance of the S83L substitution. The correlation be-
tween antibiotic resistance and diarrhoea has also been
suggested in a study that showed that diarrhoea during
travel was associated with a higher risk of acquired
ESBL-producing Enterbacteriacea into to the faecal flora
[5]. Alas, with the approach taken, we cannot exclude
that various changes in other factors, such as environ-
ment and food habits [28, 29], could have provided se-
lective advantages for pre-existing strains in the gut of
the Swedes. The Swedish participants in this study did,
however, not undergo treatment with any antibiotics
during their visit in India. Thus, there was no apparent
selection pressure that would favour pre-existing strains
carrying antibiotic resistance mutations. Consequently,
the acquisition of new strains seems like a more plaus-
ible explanation. A future research aim could be to elu-
cidate the geographical origin of resistant Escherichia
strains by employing culture methods and high-
resolution genetic strain characterization by, for ex-
ample, sequencing of multiple genomic regions. If the
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participants had taken antibiotics during their travel, it
is possible that the observed effect would have been
stronger.
The most abundant substitutions in the study were
S83L and D87N in GyrA and S80I in ParC, all of which
have been previously linked to fluoroquinolone resist-
ance. In fluoroquinolone-resistant clinical isolates, S83 is
the most common amino acid in GyrA to be substituted,
S83L is the most common substitution, and D87N is the
second most common substitution [10]. As single muta-
tions, neither substitution provides E. coli with clinically
relevant ciprofloxacin resistance (increase in ciprofloxa-
cin MIC from 0.01 mg/L to 0.38 mg/L and 0.25 mg/L,
respectively), nor are they associated with any known
significant fitness cost in competition experiments with
a wild-type strain [30]. In contrast, a double substitu-
tion of S83L and D87N provide the same protection
against quinolones as the single S83L substitution but
also introduce a fitness burden (measured relative fitness
of 0.97) [30]. In ParC, S80 is the most commonly
substituted amino acid, and S80I is the most commonly
detected substitution. Having only the single S80I substi-
tution in ParC is not associated with either an increased
ciprofloxacin MIC or a fitness cost. However, the small
fitness cost associated with S83L/D87N in GyrA is elimi-
nated if ParC acquires the S80I substitution (measured
Fig. 1 Average abundance of amino acid substitutions in the quinolone resistance determining region. Each chart represents a study group
(Swedes before travel, Swedes after travel, and Indians) and a targeted sequence (GyrA and ParC). The protein sequences of GyrA and ParC in E.
coli K-12 MG1655 [RefSeq: NC_000913.3] was used as a reference
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relative fitness of 1.01) [30]. This provides a plausible ex-
planation for the correlation between the abundance of
the two genotypes (Fig. 3). Alas, with the metagenomic
amplicon sequencing approach used on the two genes in
this study, it is impossible to determine which of the
GyrA alterations occurred in the same bacterium as the
ParC alterations. However, the detected correlation, to-
gether with the previously reported reduced fitness cost,
suggests that these alterations, at least to a large extent,
co-occur in the same bacteria. In addition to eliminating
the fitness cost for S83L/D87N double mutants, the S80I
substitution also increases the ciprofloxacin MIC to
32 ml/L, which is well above the EUCAST breakpoint
for clinical resistance in Enterobacteriaceae (1 mg/L)
[31].
It is thought that the majority of urinary tract infec-
tions caused by E. coli have their origin from the pa-
tient’s own gut flora [32]. Therefore, one could
hypothesise that there could be a correlation between
the average abundance of resistance mutations in the
gut microbiota and the frequency of fluoroquinolone-
resistant E. coli infections encountered in the clinic. The
combination of S83L in GyrA and S80I in ParC has been
reported to result in clinical resistance (ciprofloxacin
MIC 1 mg/L) but it is not associated with a fitness cost
[30]. Assuming that all observed S80I substitutions in
ParC occur in bacteria carrying the S83L substitution in
GyrA, the theoretical maximum proportion of the exam-
ined Escherichia gut communities being clinically resist-
ant to fluoroquinolone through known chromosomal
Fig. 2 Average abundance of the most commonly detected
substitutions. All substitutions detected in >5 % of all analysed reads
are included. For the quinolone resistance determining region of GyrA,
this was the substitutions S83L, D87N, and the combination thereof. In
ParC it was the S80I substitution. Error bars indicates the standard error
of the mean, and an asterisk indicates significant difference compared to
the Swedish samples collected before travel (p< 0.05)
Fig. 3 Number of observed genotypes of the quinolone resistance
determining regions in GyrA and ParC. Only genotypes detected
in > 0.5 % of the analysed reads in each sample are included. Error
bars indicates the standard error of the mean, and asterisks indicates
a significant difference compared to the Swedish samples collected
before travel (p < 0.01)
Fig. 4 Correlation between the most common substitutions in GyrA
and ParC. The relative abundance of the double substitution of S83L
and D87N in GyrA, and the S80I substitution in ParC in faecal and
environmental (Johnning et al., under review) Escherichia communities
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target gene mutations would on average be 16 % in the
Swedish samples taken prior to travel and 21 % in the
Indian samples. This does not reflect the frequency of
fluoroquinolone resistant infections, which in Sweden
was 7.9 % of invasive E. coli infections [14], and in India
could have been as high as 73 % of uropathogenic E. coli
[16]. It should be stressed that the present study did not
cover representative populations of either countries, as it
was mainly designed to examine the effect of travel.
However, the data indicate that the abundance of resist-
ance mutations in the entire Escherichia community res-
iding in the gut differs from the pathogenic portion.
The finding of a decreased number of genotypes after
travel was intriguing. We have not encountered any
studies showing that travel effects the intestinal bacterial
diversity or composition. Metagenomic sequencing of
the Swedish samples included in this study in addition
to more samples of Swedish travellers, has shown that
the overall taxonomic composition remains relatively
stable [33]. However, when only the small proportion
of the community composing of the Escherichia/Shi-
gella genera was considered, travel resulted in an on
average four-fold increase in the genus abundance
(average abundance of Escherichia/Shigella was 0.018
and 0.084 % before and after travel, respectively).
Taken together, the increased abundance of Escherichia/
Shigella and decreased number of observed genotypes of
the QRDRs of gyrA and parC, show that the faecal flora of
the Swedish travellers comprised of a larger but less vari-
able Escherichia/Shigella population after return from
India. This population also has a higher abundance of
quinolone resistance mutations.
Conclusions
Our results indicate that international travel can be associ-
ated with increased abundance of faecal bacteria carrying
chromosomal resistance mutations. Thereby, traveling
may contribute to the global dissemination of Escherichia
carrying chromosomal mutations linked to quinolone re-
sistance. Furthermore, the high abundance of genotypes
encoding GyrA and ParC with amino acid substitutions
previously linked to quinolone resistance, suggest that
these particular alterations are not associated with a fit-
ness cost in the studied environment. Amplicon sequen-
cing of metagenomic DNA proved to be a comprehensive
method to study resistance mutations in an community of
bacteria without the requirement of culturing.
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